LOPINAVIR

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
UNII 2494G1JF75
EPA CompTox DTXSID8046456

Structure

InChI Key KJHKTHWMRKYKJE-SUGCFTRWSA-N
Smiles Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
InChI
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C37H48N4O5
Molecular Weight 628.81
AlogP 4.33
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 15.0
Polar Surface Area 120.0
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 46.0

Bioactivity

Mechanism of Action Action Reference
Human immunodeficiency virus type 1 protease inhibitor INHIBITOR FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- - - 410-1000 -
Enzyme Protease Aspartic protease Aspartic protease AA clan Aspartic protease A2A subfamily
- 25 0 0-6 93-93
Enzyme Protease Cysteine protease Cysteine protease PAC clan Cysteine protease C3A subfamily
1160 3-25 0-1 0-1 -
Enzyme Protease Metallo protease Metallo protease MAE clan Metallo protease M48A subfamily
- 18400 - - -
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 8511 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 85
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 17300-17300 - - 50
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 21000 - - -
Assay Description Organism Bioactivity Reference
Effective concentration against ritonavir -resistant strains in MT-4 cells. Homo sapiens 100.0 nM
Tested for cytopathic effect of HIVIIIB in MT-4 cells in presence of 50% human serum Homo sapiens 100.0 nM
Antiviral activity against the cytopathic effects of HIV IIIB in MT-4 cells was assayed in the presence of 50% human serum Homo sapiens 100.0 nM
Antiviral activity against HIV in presence of 50% human serum in MT-4 cell was determined Homo sapiens 104.0 nM
Compound was tested for antiviral activity against HIV-IIIB in MT-4 cells in presence of 50% human serum Homo sapiens 100.0 nM
Inhibitory activity against HIV protease None 0.0013 nM
Inhibition of HIV protease at 0.5 nM Human immunodeficiency virus 1 93.0 %
Inhibitory activity (0.5 nM) against Protease None 93.0 %
Compound was tested for its inhibitory potency against HIV protease at 0.5 nM None 93.0 %
Binding affinity against ritonavir-resistant strains. Human immunodeficiency virus 1 0.004 nM
Binding affinity for human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.1 nM
Inhibition constant for human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.08 nM
Inhibitory concentration against wild type human immunodeficiency virus Human immunodeficiency virus 1 35.0 nM
Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line Human immunodeficiency virus 1 400.0 nM
Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line Human immunodeficiency virus 1 40.0 nM
Inhibitory activity against HIV1 protease at 0.5 uM Human immunodeficiency virus 1 93.0 %
Antiviral activity against HIV1 in the absence of human serum Human immunodeficiency virus 1 16.0 nM
Antiviral activity against HIV1 in the presence of 50% human serum Human immunodeficiency virus 1 67.0 nM
Antiviral activity against indinavir resistant HIV IND-R mutant strain Human immunodeficiency virus 385.0 nM
Antiviral activity against HIV1 HXB2 in MT4 cells None 40.0 nM
Antiviral activity against HIV1 EP13 in MT4 cells None 400.0 nM
Inhibition of wild type HIV1 protease Q7K mutant Human immunodeficiency virus 1 0.005 nM
Inhibition of HIV1 protease L10I/G48V/I54V/L63P/V82A mutant Human immunodeficiency virus 1 6.1 nM
Inhibition of HIV1 protease D30N/L63P/N88D mutant Human immunodeficiency virus 1 0.04 nM
Inhibition of HIV1 protease L10I/L63P/A71V/G73S/I84V/L90M mutant Human immunodeficiency virus 1 0.9 nM
Antiviral activity against wild type HIV2 in CBMCs Human immunodeficiency virus 2 4.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 182L mutation in CBMCs Human immunodeficiency virus 2 75.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 182F mutation in CBMCs Human immunodeficiency virus 2 145.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with V62A and L99F mutation in CBMCs Human immunodeficiency virus 2 496.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 150V mutation in CBMCs Human immunodeficiency virus 2 203.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M mutation in CBMCs Human immunodeficiency virus 2 481.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and L90M mutation in CBMCs Human immunodeficiency virus 2 524.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and 184V mutation in CBMCs Human immunodeficiency virus 2 375.0 nM
Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and L99F mutation in CBMCs Human immunodeficiency virus 2 414.0 nM
Antiviral activity against wild type HIV1 in CBMCs Human immunodeficiency virus 1 2.0 nM
Antiviral activity against HIV1 isolate 5512 with V321 and M46L mutation in CBMCs Human immunodeficiency virus 1 1.0 nM
Antiviral activity against HIV1 isolate 5512 with D30N, M461 and V771 mutation in CBMCs Human immunodeficiency virus 1 2.0 nM
Antiviral activity against HIV1 isolate 5512 with M36I/M and V82T mutation in CBMCs Human immunodeficiency virus 1 7.0 nM
Inhibition of HIV1 Protease M1 variant by FRET based assay Human immunodeficiency virus 1 6.1 nM
Inhibition of HIV1 Protease M2 variant by FRET based assay Human immunodeficiency virus 1 0.04 nM
Inhibition of HIV1 Protease M3 variant by FRET based assay Human immunodeficiency virus 1 0.9 nM
Antiviral activity against HIV1 infected MT4 cells by MTT method Human immunodeficiency virus 1 10.0 nM
Inhibition of HIV1 protease Human immunodeficiency virus 1 0.016 nM
Antiviral activity against HIV1 3B Human immunodeficiency virus 1 8.0 nM
Antiviral activity against HIV1 3B in presence of 50% human serum Human immunodeficiency virus 1 8.0 nM
Antiviral activity against wild type HIV1 Human immunodeficiency virus 1 3.7 nM
Antiviral activity against HIV1 mutant strain 1 Human immunodeficiency virus 1 214.0 nM
Antiviral activity against HIV1 mutant strain 2 Human immunodeficiency virus 1 251.0 nM
Antiviral activity against HIV1 mutant strain 3 Human immunodeficiency virus 1 657.0 nM
Antiviral activity against HIV1 mutant strain 4 Human immunodeficiency virus 1 66.0 nM
Antiviral activity against HIV1 mutant strain 5 Human immunodeficiency virus 1 807.0 nM
Antiviral activity against HIV1 mutant strain 6 Human immunodeficiency virus 1 411.0 nM
Antiviral activity against HIV1 mutant strain 7 Human immunodeficiency virus 1 212.0 nM
Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 7.0 nM
Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 2 2.6 nM
Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 2 4.9 nM
Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay Human immunodeficiency virus 1 31.0 nM
Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 270.0 nM
Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 160.0 nM
Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 260.0 nM
Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 24.0 nM
Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 230.0 nM
Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 310.0 nM
Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 33.0 nM
Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 34.0 nM
Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 60.0 nM
Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 190.0 nM
Antiviral activity against wild type HIV1 ERS104prc X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 7.0 nM
Antiviral activity against HIV1 MDR/TM X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 360.0 nM
Antiviral activity against HIV1 MDR/MM R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 380.0 nM
Antiviral activity against HIV1 MDR/JSL R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 700.0 nM
Antiviral activity against HIV1 MDR/B X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 300.0 nM
Antiviral activity against HIV1 MDR/C X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 310.0 nM
Antiviral activity against HIV1 MDR/G X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 160.0 nM
Antiviral activity against HIV1 92UG029 X4 subtype A in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 7.0 nM
Antiviral activity against HIV1 92UG037 subtype A R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 5.0 nM
Antiviral activity against HIV1 BaL R5 subtype B in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 5.3 nM
Antiviral activity against HIV1 97ZA003 R5 subtype C in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 7.3 nM
Antiviral activity against HIV1 92TH019 R5 subtype E in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 3.3 nM
Inhibition of wild-type HIV1 BH10 protease expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.018 nM
Inhibition of HIV1 recombinant protease D30N/N88D mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.026 nM
Inhibition of HIV1 recombinant protease M46I/A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.029 nM
Inhibition of HIV1 recombinant protease A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.06 nM
Inhibition of HIV1 recombinant protease V32I/I47A mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 2.4 nM
Inhibition of HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.029 nM
Inhibition of HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.44 nM
Inhibition of HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.5 nM
Ratio of Ki for HIV1 recombinant protease D30N/N88D mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 1.5 nM
Ratio of Ki for HIV1 recombinant protease M46I/A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 1.6 nM
Ratio of Ki for HIV1 recombinant protease A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 3.3 nM
Ratio of Ki for HIV1 recombinant protease V32I/I47A mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 130.0 nM
Ratio of Ki for HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 1.6 nM
Ratio of Ki for HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant to Ki for wild-type HIV1 BH10 protease expressed in Escherichia coli Human immunodeficiency virus 1 24.0 nM
Ratio of Ki for HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 28.0 nM
Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 by [3H]hypoxanthine uptake Plasmodium falciparum 1.7 ug.mL-1
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 1 18.0 nM
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 2 15.0 nM
Antiviral activity against HIV2 CBL-23 infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 12.0 nM
Antiviral activity against HIV2 CDC310319 isolate infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 80.0 nM
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 6.0 nM
Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 15.0 nM
Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 35.0 nM
Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 28.0 nM
Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 340.0 nM
Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 260.0 nM
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 1 passage Human immunodeficiency virus 2 15.0 nM
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 18 passages Human immunodeficiency virus 2 515.0 nM
Inhibition of HIV1 protease Human immunodeficiency virus 1 0.014 nM
Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay Human immunodeficiency virus 1 19.0 nM
Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay Human immunodeficiency virus 1 2.8 nM
Antiviral activity against wild type HIV1 isolate ERS104pre infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein Human immunodeficiency virus 1 30.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate TM infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein Human immunodeficiency virus 1 730.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate MM infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein Human immunodeficiency virus 1 720.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate C infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein Human immunodeficiency virus 1 320.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate G infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein Human immunodeficiency virus 1 140.0 nM
Antiviral activity against HIV1 Human immunodeficiency virus 1 34.0 nM
Antiviral activity against HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient Human immunodeficiency virus 1 230.0 nM
Antiviral activity against HIV1 NL4-3 Human immunodeficiency virus 1 4.4 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 18.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay in presence of 50% human serum Human immunodeficiency virus 1 152.0 nM
Metabolic stability in human liver microsomes assessed as inhibition of metabolism at 2 uM by LC/MS/MS analysis in presence of ritonavir Homo sapiens 59.0 %
Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells at 20 uM Homo sapiens 50.0 %
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 1 30.0 nM
Antiviral activity against HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 1 16.0 nM
Antiviral activity against indinavir-resistant HIV1 harboring L10R/M46I/L63P/V82T/I84V mutant protease infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 1 385.0 nM
Inhibition of HIV1 protease expressed in Escherichia coli by fluorometric assay Human immunodeficiency virus 1 1.4 nM
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay Human immunodeficiency virus 1 10.0 nM
Antiviral activity against wild type HIV1 isolate ERS104pre infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production Human immunodeficiency virus 1 34.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate G infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production Human immunodeficiency virus 1 260.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay Human immunodeficiency virus 1 18.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay Human immunodeficiency virus 1 151.0 nM
Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay Human immunodeficiency virus 1 32.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay Human immunodeficiency virus 1 30.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-17D-43T-68N/D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 30.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 5L/F-14Y/H-17G/D-43T-54I/M-62V/A-70R/K-71I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-60K/N-65E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 54M-65E-71I-74N-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 400.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-17D-40D-43I-46V-66V/A-70R/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 20.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-40D-70K-72R/K-91T/S protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 20.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-40D-43I-70K-82F-84V-85L-89V-90M-91T/L-98N/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 100.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10V/I-40D-43I-56V-70K-82F-84V-89V-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months Human immunodeficiency virus 2 100.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-61N-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-19P-33I-61N-71I-75M-84V-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 200.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-19P-61N-64V-71I-90M-95I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months Human immunodeficiency virus 2 100.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 12T-14Y-19P-40N-41D-61N-62I-96S-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 30.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 12Q-14R-17G/D-19P-61N-62I-92A protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 20.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 41D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) after 13 months Human immunodeficiency virus type 2 (ISOLATE ROD) 20.0 nM
Antiviral activity against Human immunodeficiency virus type 1 (BRU ISOLATE) after 13 months Human immunodeficiency virus type 1 (BRU ISOLATE) 30.0 nM
Antiviral activity against HIV 2 subtype H expressing 10I-40P-41Y-60H-63N-70T-73G-89L-92E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 60.0 nM
Inhibition of wild type HIV1 protease by FRET Human immunodeficiency virus 1 0.005 nM
Inhibition of multidrug resistant HIV1 protease L101I, L36P, A71V, G73S, I84V, L90M mutant by FRET Human immunodeficiency virus 1 0.9 nM
Antiviral activity against wild type Human immunodeficiency virus 1 Human immunodeficiency virus 1 1.4 nM
Antiviral activity against Human immunodeficiency virus 1 clade A isolated from HIV-AIDS patient Human immunodeficiency virus 1 1.6 nM
Antiviral activity against Human immunodeficiency virus 1 clade B isolated from HIV-AIDS patient Human immunodeficiency virus 1 1.0 nM
Antiviral activity against Human immunodeficiency virus 1 clade C isolated from HIV-AIDS patient Human immunodeficiency virus 1 1.6 nM
Antiviral activity against multidrug resistant Human immunodeficiency virus 1 harboring protease M46I, I54V, V82A and L90M mutant Human immunodeficiency virus 1 34.1 nM
Antiviral activity against multidrug resistant Human immunodeficiency virus 1 MDRC4 Human immunodeficiency virus 1 39.7 nM
Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS Human immunodeficiency virus 1 4.8 nM
Antiviral activity against HIV1 subtype B harboring protease polymorphism at M36 position and L10F, V82A mutant gene infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 196.0 nM
Antiviral activity against HIV1 subtype C harboring protease L10R, M46I, I54V, V82S mutant gene and polymorphism at M36 position infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 418.0 nM
Antiviral activity against HIV1 subtype C harboring protease L32I, M46I/M, L76V mutant gene and polymorphism at I36 position infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 157.0 nM
Antiviral activity against HIV1 subtype CRF02_AG harboring protease L76V, M46I, I84V mutant gene and polymorphism at M36 position infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 134.0 nM
Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay Human immunodeficiency virus 32.0 nM
Antiviral activity against HIV1 ERS104pre infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 32.0 nM
Antiviral activity against HIV1 MOKW infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 29.0 nM
Antiviral activity against HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 230.0 nM
Antiviral activity against HIV1 MM harboring L10I/K43T/M46L/I54V/L63P/A71V/V82A/L90M/Q92K in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 620.0 nM
Antiviral activity against HIV1 JSL harboring L10I/L24I/L33F/E35D/M36I/N37S/M46L/I54V/R57K/I62V/L63P/A71V/G73S/82A in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 740.0 nM
Antiviral activity against HIV1 A harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 320.0 nM
Antiviral activity against HIV1 B harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 250.0 nM
Antiviral activity against HIV1 C harboring L10I/I15V/K20R/L24I/M36I/M46L/I54V/I62V/L63P/K70Q/V82A/L89M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 460.0 nM
Antiviral activity against HIV1 G harboring L10I/V11I/T12E/I15V/L19I/R41K/M46L/L63P/A71T/V82A/L90M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA Human immunodeficiency virus 1 130.0 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA Human immunodeficiency virus 1 18.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA Human immunodeficiency virus 1 700.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA Human immunodeficiency virus 1 140.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA Human immunodeficiency virus 1 290.0 nM
Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA Human immunodeficiency virus 1 110.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA Human immunodeficiency virus 1 300.0 nM
Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA Human immunodeficiency virus 1 25.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by ELISA Human immunodeficiency virus 1 140.0 nM
Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay Human immunodeficiency virus 1 39.0 nM
Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay Human immunodeficiency virus 2 35.0 nM
Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay Human immunodeficiency virus type 2 (ISOLATE ROD) 28.0 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay Human immunodeficiency virus 1 46.0 nM
Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay Human immunodeficiency virus 1 120.0 nM
Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay Human immunodeficiency virus 1 37.0 nM
Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 34.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 260.0 nM
Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay Human immunodeficiency virus 1 190.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay Human immunodeficiency virus 1 330.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay Human immunodeficiency virus 1 280.0 nM
Antiviral activity against wild type HIV-1 ERS104 pre infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 31.0 nM
Antiviral activity against HIV-1 MDR/C infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 437.0 nM
Antiviral activity against HIV-1 MDR/G infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 181.0 nM
Antiviral activity against HIV-1 MDR/TM infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 423.0 nM
Antiviral activity against HIV-1 MDR/MM infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 762.0 nM
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation Homo sapiens 410.0 nM
Inhibition of HIV1 subtype C protease expressed in Escherichia coli BL21 assessed as hydrolysis of substrate using chromogenic substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 by spectrophotometric analysis Human immunodeficiency virus 1 25.0 nM
Inhibition of HIV1 subtype C protease Q7K mutant expressed in Escherichia coli BL21 (DE3) pLysS using Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 as substrate by spectrophotometry Human immunodeficiency virus 1 25.0 nM
Cytotoxicity against human MT4 cells after 5 days by XTT assay Homo sapiens 35.0 nM
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay Human immunodeficiency virus 1 18.0 nM
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay in presence of 50% human serum Human immunodeficiency virus 1 152.0 nM
Antimalarial activity against chloroquine resistant, mefloquine sensitive Plasmodium falciparum W2 infected in human erythrocytes by [3H]-hypoxanthine incorporation assay Plasmodium falciparum 1.7 ug.mL-1
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Human immunodeficiency virus 1 160.0 nM
Inhibition of South African HIV1 subtype C protease expressed in Escherichia coli BL21S4 (DE3)pLysS cells using Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 as substrate by spectrophotometry Human immunodeficiency virus 1 25.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells Human immunodeficiency virus 1 13.2 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M1 expressing protease L10I, M46I, I64V, I84V, L90M, I93L mutant infected in human MT4 cells Human immunodeficiency virus 1 114.6 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M2 expressing protease L10I, I13V, M46I, I50V, L63P, L76V mutant infected in human MT4 cells Human immunodeficiency virus 1 307.3 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M3 expressing protease L10I, K20R, M36I, G48V, I62V, A71V, V82A, I93L mutant infected in human MT4 cells Human immunodeficiency virus 1 32.1 nM
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells in presence of 50% human serum Human immunodeficiency virus 1 63.2 nM
Binding affinity to wild type HIV1 protease Human immunodeficiency virus 1 0.005 nM
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens 85.8 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 84.6 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 86.4 %
Inhibition of wild type C-South African Human immunodeficiency virus 1 protease using chromogenic peptide H-1048 as substrate by UV spectrophotometric analysis Human immunodeficiency virus 1 25.0 nM
Inhibition of C-south african HIV-1 protease assessed as hydrolysis of the chromogenic peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 Human immunodeficiency virus 1 25.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/K20R/M36I/G48V/ I62V/A71V/V82A/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 32.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/I13V/M46I/I50V/L63P/L76V protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 310.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/M46I/I64V/I84V/L90M/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 110.0 nM
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication in presence of 50% human plasma Human immunodeficiency virus 1 63.0 nM
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 13.0 nM
Inhibition of HIV-1 multidrug-resistant protease 769 preincubated for 20 mins by FRET analysis Human immunodeficiency virus 1 16.0 nM
Inhibition of HIV-1 NL4-3 wild type protease expressed in Escherichia coli preincubated for 20 mins by FRET analysis Human immunodeficiency virus 1 2.5 nM
Inhibition of HIV1 protease using fluorogenic hexapeptide substrate (2-aminobenzoyl)Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg by fluorimeter Human immunodeficiency virus 1 0.0371 nM
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay Human immunodeficiency virus 1 5.6 nM
Binding affinity to HIV1 protease Human immunodeficiency virus 1 0.0013 nM
Binding affinity to HIV1 protease I47A mutant Human immunodeficiency virus 1 1.1 nM
Antiviral activity against amprenavir-resistant HIV1 NL4-3 harboring protease L10F/V32I/L33F/M46L/I54M/A71V mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 310.0 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 20.0 nM
Antiviral activity against nelfinavir-resistant HIV1 NL4-3 harboring protease L10F/K20T/D30N/K45I/A71V/V77I mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 42.0 nM
Antiviral activity against indinavir-resistant HIV1 NL4-3 harboring protease L10F/L24I/M46I/I54V/L63P/A71V/G73S/V82T mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 170.0 nM
Antiviral activity against atazanavir-resistant HIV1 NL4-3 harboring protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 330.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days in absence of human serum by MTT assay Human immunodeficiency virus 1 30.0 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 32.0 nM
Antiviral activity against APV resistant HIV1 harboring protease L10F/M46I/I50V/I85V mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 390.0 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 6.0 nM
Antiviral activity against Atazanavir-resistant HIV1 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 311.0 nM
Antiviral activity against amprenavir-resistant HIV1 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 218.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 56.55 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.46 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 1.914 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 98.37 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 9.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 98.37 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 9.17 %
Inhibition of HIV1 NL4-3 protease expressed in Escherichia coli TAP-106 cells using EDANS/DABCYL-labelled 10-amino acid containing protease cleavage site as substrate preincubated for 1 hr followed by substrate addition and measured for 60 mins by FRET assay Human immunodeficiency virus 1 0.005 nM
Inhibition of HIV1 NL4-3 protease I84V mutant expressed in Escherichia coli TAP-106 cells using EDANS/DABCYL-labelled 10-amino acid containing protease cleavage site as substrate preincubated for 1 hr followed by substrate addition and measured for 60 mins by FRET assay Human immunodeficiency virus 1 0.051 nM
Inhibition of HIV1 NL4-3 protease I50V/A71V mutant expressed in Escherichia coli TAP-106 cells using EDANS/DABCYL-labelled 10-amino acid containing protease cleavage site as substrate preincubated for 1 hr followed by substrate addition and measured for 60 mins by FRET assay Human immunodeficiency virus 1 0.061 nM
Antiviral activity against wild-type HIV1 NL4-3 infected in human TZM-bl cells infected with supernatants from virus-infected human 293T cells treated with compound for 18 hrs assessed as reduction in viral replication by luciferase assay Human immunodeficiency virus 1 12.0 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells incubated for 7 days by fully automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 27.0 nM
Antiviral activity against ATV-resistant HIV1 infected in human MT4 cells incubated for 7 days by fully automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 340.0 nM

Environmental Exposure

Environmental Exposure Map
Countries
Croatia
Czech Republic
Romania
Serbia
South Africa

Cross References

Resources Reference
ChEBI 31781
ChEMBL CHEMBL729
DrugBank DB01601
DrugCentral 1601
FDA SRS 2494G1JF75
Human Metabolome Database HMDB0015539
KEGG C12871
PDB AB1
PharmGKB PA450264
PubChem 92727
SureChEMBL SCHEMBL21775
ZINC ZINC000003951740
CONTENTS